Lord, Abbett & Co’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-560,040
| Closed | -$96.4M | – | 713 |
|
|
2021
Q3 | $96.4M | Buy |
560,040
+108,953
| +24% | +$14.3M | 0.23% | 138 |
|
|
2021
Q2 | $56.6M | Sell |
451,087
-16,558
| -4% | -$2.09M | 0.14% | 226 |
|
|
2021
Q1 | $63.4M | Sell |
467,645
-451,320
| -49% | -$58.3M | 0.16% | 200 |
|
|
2020
Q4 | $118M | Sell |
918,965
-115,019
| -11% | -$13.5M | 0.31% | 95 |
|
|
2020
Q3 | $116M | Buy |
1,033,984
+756,387
| +272% | +$75.3M | 0.37% | 73 |
|
|
2020
Q2 | $26.4M | Buy |
277,597
+20,980
| +8% | +$2.02M | 0.09% | 331 |
|
|
2020
Q1 | $23.1M | Buy |
+256,617
| New | +$19.9M | 0.1% | 298 |
|
|
2018
Q4 | – | Sell |
-124,385
| Closed | -$7.12M | – | 850 |
|
|
2018
Q3 | $7.12M | Buy |
124,385
+10,051
| +9% | +$494K | 0.02% | 684 |
|
|
2018
Q2 | $5.55M | Sell |
114,334
-2,180
| -2% | -$79.4K | 0.02% | 726 |
|
|
2018
Q1 | $4.56M | Buy |
116,514
+35,382
| +44% | +$1.5M | 0.01% | 743 |
|
|
2017
Q4 | $3.44M | Sell |
81,132
-1,972
| -2% | -$74K | 0.01% | 806 |
|
|
2017
Q3 | $3.1M | Sell |
83,104
-4,839
| -6% | -$168K | 0.01% | 820 |
|
|
2017
Q2 | $2.67M | Sell |
87,943
-1,488
| -2% | -$43.1K | 0.01% | 841 |
|
|
2017
Q1 | $2.37M | Sell |
89,431
-1,000
| -1% | -$26.4K | 0.01% | 828 |
|
|
2016
Q4 | $2.31M | Sell |
90,431
-72,614
| -45% | -$2.3M | 0.01% | 820 |
|
|
2016
Q3 | $5.9M | Buy |
163,045
+18,112
| +12% | +$600K | 0.02% | 700 |
|
|
2016
Q2 | $4.92M | Buy |
144,933
+19,469
| +16% | +$633K | 0.02% | 713 |
|
|
2016
Q1 | $3.31M | Sell |
125,464
-25,776
| -17% | -$750K | 0.01% | 778 |
|
|
2015
Q4 | $7.37M | Buy |
151,240
+72,815
| +93% | +$2.62M | 0.02% | 658 |
|
|
2015
Q3 | $1.95M | Sell |
78,425
-85,272
| -52% | -$2.56M | 0.01% | 849 |
|
|
2015
Q2 | $5.18M | Sell |
163,697
-216,972
| -57% | -$7M | 0.01% | 762 |
|
|
2015
Q1 | $14.5M | Buy |
380,669
+134,767
| +55% | +$5.36M | 0.04% | 545 |
|
|
2014
Q4 | $9.58M | Buy |
245,902
+160,235
| +187% | +$5.58M | 0.02% | 625 |
|
|
2014
Q3 | $2.59M | Sell |
85,667
-35,016
| -29% | -$986K | 0.01% | 850 |
|
|
2014
Q2 | $4.1M | Buy |
120,683
+10,318
| +9% | +$345K | 0.01% | 831 |
|
|
2014
Q1 | $3.81M | Buy |
110,365
+11,165
| +11% | +$504K | 0.01% | 834 |
|
|
2013
Q4 | $3.93M | Buy |
+99,200
| New | +$2.39M | 0.01% | 899 |
|
Lord, Abbett & Co's XLRN Position: Q4 2021 in Review
Lord, Abbett & Co sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 560,040 shares — an estimated $96.4M sold.
Lord, Abbett & Co first reported a position in XLRN in Q4 2013 and held it in 27 quarters. The position peaked at $118M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Lord, Abbett & Co reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Lord, Abbett & Co sold 560,040 Acceleron Pharma shares in Q4 2021, an estimated $96.4M.
- Lord, Abbett & Co first reported a position in Acceleron Pharma in Q4 2013 and held it in 27 quarters.
- Lord, Abbett & Co's Acceleron Pharma position peaked at $118M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Lord, Abbett & Co's 13F filing for Q4 2021, filed 11 Feb 2022.